Last reviewed · How we verify

AT-001 — Competitive Intelligence Brief

AT-001 (AT-001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense oligonucleotide. Area: Cardiovascular.

phase 3 Antisense oligonucleotide Apolipoprotein(a) mRNA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AT-001 (AT-001) — NYU Langone Health. AT-001 is an antisense oligonucleotide that reduces production of lipoprotein(a) by targeting hepatic apolipoprotein(a) synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AT-001 TARGET AT-001 NYU Langone Health phase 3 Antisense oligonucleotide Apolipoprotein(a) mRNA
Qalsody TOFERSEN Biogen Ma marketed Antisense Oligonucleotide [EPC] Superoxide dismutase 1 (SOD1) mRNA 2023-01-01
Amondys 45 CASIMERSEN Sarepta marketed Antisense Oligonucleotide [EPC] exon 53 of dystrophin pre-mRNA 2021-01-01
Vyondys 53 GOLODIRSEN Sarepta marketed Antisense Oligonucleotide [EPC] exon 53 of dystrophin pre-mRNA 2019-01-01
Exondys 51 ETEPLIRSEN Sarepta marketed Antisense Oligonucleotide [EPC] exon 51 of dystrophin pre-mRNA 2016-01-01
Kynamro MIPOMERSEN Kastle Theraps Llc marketed Antisense Oligonucleotide 2013-01-01
PF-07852352 Influenza saRNA 1 pf-07852352-influenza-sarna-1 Pfizer marketed antisense oligonucleotide influenza virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense oligonucleotide class)

  1. Ionis Pharmaceuticals, Inc. · 3 drugs in this class
  2. Sarepta Therapeutics, Inc. · 2 drugs in this class
  3. Isarna Therapeutics GmbH · 1 drug in this class
  4. Leadiant Biosciences, Inc. · 1 drug in this class
  5. NYU Langone Health · 1 drug in this class
  6. Avidity Biosciences, Inc. · 1 drug in this class
  7. Ultragenyx Pharmaceutical Inc · 1 drug in this class
  8. European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AT-001 — Competitive Intelligence Brief. https://druglandscape.com/ci/at-001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: